30 research outputs found
Should couples with unexplained infertility have three to six cycles of intrauterine insemination with ovarian stimulation or in vitro fertilization as first-line treatment?
No full textFarquhar, C (corresponding author), Univ Auckland, 85 Pk Rd, Auckland 1010, New Zealand.
[email protected]
Inguinal ovary after controlled ovarian hyperstimulation-infrequent, infrequently recognized, or observer variation?
No full text[No abstract available]BAZI T, 2006, FERTIL STERIL, V85, pE5; Hinckley MD, 2003, FERTIL STERIL, V80, P445, DOI 10.1016-S0015-0282(03)00668-X; Idil M, 2006, FERTIL STERIL, V85, DOI 10.1016-j.fertnstert.2005.11.066; Mayer V, 1941, ARCH SURG-CHICAGO, V43, P397; Ombelet W, 2003, HUM REPROD, V18, P858, DOI 10.1093-humrep-deg1911
Reversal of Dialysis-Dependent Anti–Glomerular Basement Membrane Disease Using Plasma Exchange, Glucocorticosteroids, and Rituximab
No full textReversal of Dialysis-Dependent Anti-Glomerular Basement Membrane Disease Using Plasma Exchange, Glucocorticosteroids, and Rituximab
No full textstatus: Publishe
Author response: Evaluation of hyperacute infarct volume using ASPECTS and brain CT perfusion core volume
No full textThe ABC of pneumococcal infections and vaccination in patients with chronic kidney disease
No full textBackground. In the general population, pneumococcal polysaccharide vaccines (PPV) decrease the incidence of invasive pneumococcal disease (IPD) whereas the impact on the prevention of noninvasive pneumococcal disease is less clear. As compared with PPV, pneumococcal conjugate vaccines (PCV) provoke a higher, longer-lasting immune response resulting in a 45% decreased incidence in vaccine-type pneumonia, and a 75% decrease in vaccine-type IPD. Methods. Literature review on pneumococcal vaccination in end-stage renal disease. Results. As compared with the general population, patients with chronic kidney disease (CKD) suffer increased mortality and morbidity from pneumococcal disease (PD), being up to 10-fold for those treated with dialysis. Numerous, usually small and methodological heterogeneous studies demonstrate that PPV provokes a serological response in dialysis patients, kidney transplant recipients, children with nephrotic syndrome and CKD patients receiving immunosuppressive medication. This response is of less intensity and duration than in healthy controls. Similar observations were made for the PCV. The protective value of these vaccine-elicited anti-pneumococcal antibodies in the CKD population remains to be substantiated. For patients treated with dialysis, epidemiological data demonstrate a correlation-which does not equal causality-between pneumococcal vaccination status and a slightly decreased total mortality. Clinical outcome data on the effectiveness of pneumococcal vaccination in the prevention of morbidity and mortality in the CKD population are lacking. Conclusions. Awaiting better evidence, pneumococcal vaccination should be advocated in all patients with CKD, as early in their disease course as possible. The ACIP schedule recommends a PCV-13 prime vaccination followed by a PPV-23 repeated vaccine at least 8 weeks later in pneumococcal non-vaccinated patients, and a PCV-13 vaccine at least 1 year after the latest PPV vaccine in previously vaccinated patients. In the UK, vaccination with PPV-23 only is recommended. There exist no good data supporting re-vaccination after 5 years in the dialysis population.SCOPUS: re.jinfo:eu-repo/semantics/publishe
Challenges in Preparing and Implementing a Clinical Trial at Field Level in an Ebola Emergency: A Case Study in Guinea, West Africa
No full textDuring the large Ebola outbreak that affected West Africa in 2014 and 2015, studies were launched to evaluate potential treatments for the disease. A clinical trial to evaluate the effectiveness of the antiviral drug favipiravir was conducted in Guinea. This paper describes the main challenges of the implementation of the trial in the Ebola treatment center of Guéckédou. Following the principles of the Good Clinical Research Practices, we explored the aspects of the community's communication and engagement, ethical conduct, trial protocol compliance, informed consent of participants, ongoing benefit/risk assessment, record keeping, confidentiality of patients and study data, and roles and responsibilities of the actors involved. We concluded that several challenges have to be addressed to successfully implement a clinical trial during an international medical emergency but that the potential for collaboration between research teams and humanitarian organizations needs to be highlighted
Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology
No full textBiomedical science is rapidly developing in terms of more transparency, openness and reproducibility of scientific publications. This is even more important for all studies that are based on results from basic semen examination. Recently two concordant documents have been published: the 6th edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen, and the International Standard ISO 23162:2021. With these tools, we propose that authors should be instructed to follow these laboratory methods in order to publish studies in peer-reviewed journals, preferable by using a checklist as suggested in an Appendix to this article. VC The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology
Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa
No full text
